Practical ICU pharmacology: standard infusion dilutions and rate maths for vasoactive, sedative and other common infusions, dosing in obesity, AKI/CRRT and augmented renal clearance, liver dysfunction, QT-prolonging drugs and key interactions, and IV compatibility and line safety.
6 topics
- 01
Standard infusion dilutions and rate maths
Use one standard concentration per drug across the ICU, label the final concentration, and convert doses to mL/h with a single formula: rate (mL/h) = dose (mcg/kg/min) × weight (kg) × 60 ÷ concentration (mcg/mL). Double-check every high-alert infusion.
6 stepsAlgorithm4 dosesNew - 02
Drug dosing in obesity
Pick the dosing weight per drug: lipophilic loading doses and some antimicrobials by actual weight, most maintenance infusions and neuromuscular blockers by ideal or adjusted weight, and titrate sedatives to effect. Use therapeutic drug monitoring where available.
6 stepsAlgorithm1 dosesNew - 03
Dosing in AKI, CRRT and augmented renal clearance
Never reduce loading doses for renal function. Adjust maintenance doses to measured or estimated clearance, recognising that creatinine is unreliable in unstable AKI, that CRRT removes many antibiotics, and that young septic or trauma patients often clear drugs faster than normal.
6 stepsAlgorithm1 dosesNew - 04
Dosing in liver dysfunction
No liver test predicts drug clearance well. In cirrhosis and acute liver failure prefer drugs with short half-lives or non-hepatic elimination, avoid long-acting sedatives, lower and titrate high-extraction and highly protein-bound drugs, and watch for encephalopathy and bleeding.
5 stepsAlgorithmNew - 05
QT prolongation, torsades and key ICU drug interactions
Stack-check QT drugs and risk factors (low K/Mg, bradycardia, female sex, structural heart disease). Stop offending drugs when QTc exceeds 500 ms or rises more than 60 ms, give IV magnesium for torsades, and watch the handful of interactions that cause real ICU harm.
4 stepsAlgorithm1 dosesNew - 06
IV compatibility, line management and extravasation
Give vasoactives through a dedicated labelled lumen, never Y-site unknown combinations, keep blood, parenteral nutrition and bicarbonate separate, and recognise extravasation early. Peripheral vasopressors are acceptable short-term with a good proximal vein, hourly checks and an extravasation plan.
5 stepsAlgorithm1 dosesNew
Drugs in this module
Doses written for this module's context. The same drug may read differently in another module.
Noradrenaline (norepinephrine)
Alpha-1 > beta-1 agonist vasopressor
Noradrenaline (norepinephrine)
Alpha-1 > beta-1 agonist vasopressor
- Indications
- First-line vasopressor in septic and most vasodilatory shock.
- Adult dose
- 0.05-0.5 mcg/kg/min (higher in refractory shock); start ~0.05-0.1 mcg/kg/min titrated to MAP ≥ 65 mmHg.
- Preparation (India)
- 2 mg/2 mL ampoules. Common syringe: 8 mg in 50 mL (160 mcg/mL) or 4 mg in 50 mL (80 mcg/mL) of NS or D5.
- Cautions
- Extravasation necrosis; peripheral use acceptable short-term via a good proximal vein with monitoring. Digital/mesenteric ischaemia at high doses.
Adrenaline (epinephrine)
Alpha and beta agonist
Adrenaline (epinephrine)
Alpha and beta agonist
- Indications
- Second vasopressor/inotrope in shock; anaphylaxis infusion.
- Adult dose
- 0.05-0.5 mcg/kg/min infusion.
- Preparation (India)
- 1 mg/mL ampoules. Syringe: 4 mg in 50 mL (80 mcg/mL).
- Cautions
- Lactate rise (beta-2), tachyarrhythmia, hyperglycaemia.
Vasopressin
V1 receptor agonist
Vasopressin
V1 receptor agonist
- Indications
- Add-on in septic shock when noradrenaline doses are escalating (commonly 0.25-0.5 mcg/kg/min; SSC 2026).
- Adult dose
- 0.03 U/min fixed (up to 0.04 U/min); not weight-based.
- Preparation (India)
- 20 U/mL 1 mL ampoules. Syringe: 20 U in 50 mL (0.4 U/mL); 0.03 U/min = 4.5 mL/h.
- Cautions
- Digital, mesenteric and myocardial ischaemia; hyponatraemia. Terlipressin is a different drug (bolus doses in mg), and SSC 2026 suggests against it in septic shock.
Dobutamine
Beta-1 agonist inotrope
Dobutamine
Beta-1 agonist inotrope
- Indications
- Low cardiac output with adequate MAP and filling.
- Adult dose
- 2.5-20 mcg/kg/min.
- Preparation (India)
- 250 mg vials/ampoules (volume varies by brand). Syringe: 250 mg in 50 mL (5000 mcg/mL).
- Cautions
- Tachycardia, arrhythmia, hypotension from beta-2 vasodilatation.
Glyceryl trinitrate (nitroglycerin)
Nitrate venodilator
Glyceryl trinitrate (nitroglycerin)
Nitrate venodilator
- Indications
- Hypertensive acute pulmonary oedema, ACS with ongoing pain or hypertension.
- Adult dose
- 5-200 mcg/min titrated every 3-5 min (high-dose boluses used in SCAPE).
- Preparation (India)
- 5 mg/mL ampoules (5 mL = 25 mg). Syringe: 50 mg in 50 mL (1 mg/mL = 1000 mcg/mL); 10 mcg/min = 0.6 mL/h.
- Cautions
- Hypotension in RV infarct or preload dependence; avoid within 24-48 h of PDE-5 inhibitors; PVC adsorption (use non-PVC sets).
Midazolam
Benzodiazepine
Midazolam
Benzodiazepine
- Indications
- Sedation when propofol/dexmedetomidine unsuitable; status epilepticus.
- Adult dose
- Infusion 0.02-0.1 mg/kg/h (use lowest effective, daily interruption).
- Preparation (India)
- 1 mg/mL (5 mL) and 5 mg/mL (1 mL, 10 mL) ampoules. Syringe: 50 mg in 50 mL (1 mg/mL).
- Cautions
- Accumulates in obesity, AKI (active metabolite) and liver failure; CYP3A4 inhibitors (azoles, macrolides) prolong effect; delirium.
Fentanyl
Synthetic opioid
Fentanyl
Synthetic opioid
- Indications
- Analgesia-first sedation in ventilated patients.
- Adult dose
- Infusion 0.5-2 mcg/kg/h (typical 25-150 mcg/h) dosed on ideal/adjusted weight in obesity.
- Preparation (India)
- 50 mcg/mL in 2 mL and 10 mL ampoules. Syringe: 500 mcg in 50 mL (10 mcg/mL) or neat 50 mcg/mL.
- Cautions
- Context-sensitive accumulation with prolonged infusion and obesity; chest wall rigidity with rapid bolus; CYP3A4 interactions; serotonin syndrome with linezolid/SSRIs.
Propofol
GABA-A agonist hypnotic
Propofol
GABA-A agonist hypnotic
- Indications
- Light sedation in ventilated patients; refractory status epilepticus.
- Adult dose
- 5-50 mcg/kg/min (0.3-3 mg/kg/h); avoid > 4 mg/kg/h for > 48 h.
- Preparation (India)
- 1% (10 mg/mL) 20 mL ampoules and 50 mL vials; run neat. 2% available.
- Cautions
- Hypotension; propofol infusion syndrome (acidosis, rhabdomyolysis, arrhythmia, hypertriglyceridaemia); lipid calories 1.1 kcal/mL; change giving set every 12 h (6-12 h for open vials).
Dexmedetomidine
Alpha-2 agonist
Dexmedetomidine
Alpha-2 agonist
- Indications
- Light sedation, agitation/delirium, facilitation of NIV and extubation.
- Adult dose
- 0.2-1.4 mcg/kg/h; loading doses usually omitted in ICU because of bradycardia/hypotension.
- Preparation (India)
- 100 mcg/mL ampoules (1 mL, 2 mL). Syringe: 200 mcg in 50 mL (4 mcg/mL).
- Cautions
- Bradycardia, hypotension; does not provide deep sedation or amnesia.
Regular (soluble) insulin
Insulin
Regular (soluble) insulin
Insulin
- Indications
- DKA/HHS, ICU hyperglycaemia > 180 mg/dL, hyperkalaemia.
- Adult dose
- DKA 0.1 U/kg/h (or 0.14 U/kg/h without bolus); ICU glucose by protocol targeting 140-180 mg/dL.
- Preparation (India)
- 40 U/mL (U-40) and 100 U/mL vials. Syringe: 50 U in 50 mL NS (1 U/mL).
- Cautions
- U-40 vs U-100 confusion; adsorption to tubing (prime the line); hypokalaemia and hypoglycaemia.
Unfractionated heparin
Indirect thrombin/Xa inhibitor
Unfractionated heparin
Indirect thrombin/Xa inhibitor
- Indications
- Therapeutic anticoagulation where rapid reversal or AKI precludes LMWH; CRRT circuits.
- Adult dose
- VTE: 80 U/kg bolus then 18 U/kg/h (ACS: 60 U/kg max 4000 U, then 12 U/kg/h max 1000 U/h), adjusted to aPTT/anti-Xa.
- Preparation (India)
- 5000 U/mL 5 mL vials (25,000 U). Syringe: 25,000 U in 50 mL (500 U/mL).
- Cautions
- Use actual weight with a cap per local nomogram in obesity; HIT; bleeding.
Amiodarone
Class III antiarrhythmic
Amiodarone
Class III antiarrhythmic
- Indications
- AF with rapid ventricular response in haemodynamically fragile patients; VT; shock-refractory VF.
- Adult dose
- 300 mg IV over 20-60 min, then 900 mg over 24 h.
- Preparation (India)
- 150 mg/3 mL ampoules. Dilute in 5% dextrose; infusions > 2 mg/mL via central line; use in-line filter per product.
- Cautions
- Phlebitis peripherally; hypotension; QT prolongation (TdP uncommon); raises digoxin and warfarin effect.
Magnesium sulphate
Electrolyte / antiarrhythmic
Magnesium sulphate
Electrolyte / antiarrhythmic
- Indications
- Torsades de pointes; hypomagnesaemia; QT-risk mitigation.
- Adult dose
- TdP: 2 g IV over 1-2 min (pulseless) or 10-15 min; repeat or infuse 0.5-1 g/h.
- Preparation (India)
- 50% w/v 2 mL ampoules (1 g = ~4 mmol).
- Cautions
- Hypotension with rapid infusion; accumulates in AKI (monitor levels and reflexes).
Vancomycin
Glycopeptide antibiotic
Vancomycin
Glycopeptide antibiotic
- Indications
- MRSA and other resistant Gram-positive infection.
- Adult dose
- Loading 20-35 mg/kg actual body weight (max ~3 g), then 15-20 mg/kg every 8-12 h adjusted to AUC 400-600 or trough levels.
- Preparation (India)
- 500 mg and 1 g vials; infuse ≤ 10 mg/min (1 g over ≥ 1 h).
- Cautions
- Nephrotoxicity (especially with piperacillin-tazobactam), vancomycin infusion reaction with fast infusion.
Phentolamine
Alpha-adrenergic blocker
Phentolamine
Alpha-adrenergic blocker
- Indications
- Extravasation of noradrenaline, adrenaline, dopamine or vasopressin.
- Adult dose
- 5-10 mg diluted in 10 mL NS, infiltrated subcutaneously around the extravasation site within 12 h.
- Preparation (India)
- 10 mg/mL ampoules – supply is irregular in India; keep in the ICU or know the alternative (topical nitroglycerin, SC terbutaline) per local policy.
- Cautions
- Hypotension, tachycardia.
Module references (12)
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12

